Next Article in Journal
Public Health Risks Associated with Tetrodotoxin and Its Analogues in European Waters: Recent Advances after The EFSA Scientific Opinion
Next Article in Special Issue
Venom Toxins as Potential Targeted Therapies
Previous Article in Journal
Correction: Pestka, J.J., et al. Sex Is a Determinant for Deoxynivalenol Metabolism and Elimination in the Mouse. Toxins 2017, 9, 240
Previous Article in Special Issue
A Hylarana latouchii Skin Secretion-Derived Novel Bombesin-Related Pentadecapeptide (Ranatensin-HLa) Evoke Myotropic Effects on the in vitro Rat Smooth Muscles
Article

Bee Venom Alleviates Atopic Dermatitis Symptoms through the Upregulation of Decay-Accelerating Factor (DAF/CD55)

1
Graduate School of Biotechnology, Kyung Hee University, Yongin 17104, Korea
2
Skin Biotechnology Center, Kyung Hee University, Yongin 17104, Korea
*
Authors to whom correspondence should be addressed.
Toxins 2019, 11(5), 239; https://doi.org/10.3390/toxins11050239
Received: 20 March 2019 / Revised: 21 April 2019 / Accepted: 24 April 2019 / Published: 26 April 2019
(This article belongs to the Special Issue Venom and Toxin as Targeted Therapy)
Bee venom (BV)—a complex mixture of peptides and toxic proteins including phospholipase A2 and melittin—promotes blood clotting. In this study, we investigated the anti-atopic properties of BV and the mechanism associated with its regulation of the complement system. BV treatment upregulated the mRNA and protein levels of CD55 in THP-1 cells. Further experiments revealed that the phosphorylation of ERK was associated with upregulation of CD55. A complement-dependent cytotoxicity assay and a bacteria-killing assay showed that BV inactivated the complement system through the induction of CD55. The serum levels of C3 convertase (C3C) and Membrane attack complex (MAC) increased, while CD55 decreased in mice with AD-like lesions from DNCB treatment. However, the levels were inverted when the AD-like mice were treated with BV using subcutaneous injection, and we observed that the AD symptoms were alleviated. BV is often used to treat AD but its mechanism has not been elucidated. Here, we suggest that BV alleviates AD through the inactivation of the complement system, especially by the induction of CD55. View Full-Text
Keywords: Bee venom; complement system; decay accelerating factor; atopic dermatitis; complement dependent cytotoxicity; membrane attack complex Bee venom; complement system; decay accelerating factor; atopic dermatitis; complement dependent cytotoxicity; membrane attack complex
Show Figures

Figure 1

MDPI and ACS Style

Kim, Y.; Lee, Y.-W.; Kim, H.; Chung, D.K. Bee Venom Alleviates Atopic Dermatitis Symptoms through the Upregulation of Decay-Accelerating Factor (DAF/CD55). Toxins 2019, 11, 239. https://doi.org/10.3390/toxins11050239

AMA Style

Kim Y, Lee Y-W, Kim H, Chung DK. Bee Venom Alleviates Atopic Dermatitis Symptoms through the Upregulation of Decay-Accelerating Factor (DAF/CD55). Toxins. 2019; 11(5):239. https://doi.org/10.3390/toxins11050239

Chicago/Turabian Style

Kim, Yenny, Youn-Woo Lee, Hangeun Kim, and Dae K. Chung 2019. "Bee Venom Alleviates Atopic Dermatitis Symptoms through the Upregulation of Decay-Accelerating Factor (DAF/CD55)" Toxins 11, no. 5: 239. https://doi.org/10.3390/toxins11050239

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop